In animal models of non-small cell lung cancer (NSCLC), combination of an SHP-2 inhibitor with anti-PD-L1 agents was associated with more pronounced anticancer immune responses and greater efficacy of radiotherapy [48]. Here, CD274 is linked to non-small cell lung carcinoma.